Novartis Joins Ensemble To Develop An Oral IL-17 Blocker
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is the latest big pharma to partner with Ensemble to develop oral small molecules against traditional biologic targets. Novartis will develop Ensemble’s synthetic macrocycle drug targeting IL-17, a pathway the big pharma knows well.